Interleukin (IL)-12 and IL-23 Are Key Cytokines for Immunity against Salmonella in Humans by MacLennan, Calman et al.
 
 
Interleukin (IL)-12 and IL-23 Are Key Cytokines for
Immunity against Salmonella in Humans
MacLennan, Calman; Fieschi, C; Lammas, David; Picard, C; Dorman, SE; Sanal, O;
MacLennan, JM; Holland, SM; Ottenhoff, TH; Casanova, JL; Kumararatne, Dinakantha
DOI:
10.1086/425021
Citation for published version (Harvard):
MacLennan, C, Fieschi, C, Lammas, D, Picard, C, Dorman, SE, Sanal, O, MacLennan, JM, Holland, SM,
Ottenhoff, TH, Casanova, JL & Kumararatne, D 2004, 'Interleukin (IL)-12 and IL-23 Are Key Cytokines for
Immunity against Salmonella in Humans', The Journal of Infectious Diseases, vol. 190, no. 10, pp. 1755-7.
https://doi.org/10.1086/425021
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
BRIEF REPORT • JID 2004:190 (15 November) • 1755
B R I E F R E P O R T
Interleukin (IL)–12 and IL-23
Are Key Cytokines for Immunity
against Salmonella in Humans
Calman MacLennan,1,10 Claire Fieschi,7 David A. Lammas,1
Capucine Picard,7 Susan E. Dorman,4 Ozden Sanal,6
Jenny M. MacLennan,3 Steven M. Holland,5 Tom H. M. Ottenhoff,9
Jean-Laurent Casanova,7,8 and Dinakantha S. Kumararatne2
1Medical Research Council Centre for Immune Regulation, Division of Immunity
and Infection, University of Birmingham, Birmingham, and 2Department
of Biochemistry and Clinical Immunology, Addenbrookes Hospital, Cambridge,
and 3Peter Medawar Building, Department of Zoology, University of Oxford,
Oxford, United Kingdom; 4Center for Tuberculosis Research, Johns Hopkins
University School of Medicine, Baltimore, and 5Immunopathogenesis Section,
Laboratory of Host Defenses, National Institute of Allergy and Infectious
Diseases, National Institutes of Health, Bethesda, Maryland; 6Immunology
Division, Hacettepe University Children’s Hospital, Ankara, Turkey; 7Laboratory
of Human Genetics of Infectious Diseases, University of Paris Rene´ Descartes,
INSERM U550, Necker Medical School, and 8Pediatric Immunology
and Hematology Unit, Necker Hospital, Paris, France; 9Department
of Immunohematology and Blood Transfusion, Leids Universitair Medisch
Centrum, Leiden, The Netherlands; 10Malawi-Liverpool-Wellcome Trust Clinical
Research Programme, College of Medicine, Blantyre, Malawi
Patients with inherited deficiency of the interleukin (IL)–12/
IL-23–interferon (IFN)–g axis show increased susceptibility to
invasive disease caused by the intramacrophage pathogens sal-
monellae and mycobacteria. We analyzed data on 154 patients
with such deficiency. Significantly more patients with IL-12/
IL-23–component deficiency had a history of salmonella dis-
ease than did those with IFN-g–component deficiency. Salmo-
nella disease was typically severe, extraintestinal, and caused
by nontyphoidal serovars. These findings strongly suggest
that IL-12/IL-23 is a key cytokine for immunity against sal-
monella in humans and that IL-12/IL-23 mediates this pro-
tective effect partly through IFN-g–independent pathways.
Investigation of the IL-12/IL-23–IFN-g axis should be con-
sidered in patients with invasive salmonella disease.
Immunity against salmonella is complex, but insights may be
gained from studies of humans with immunodeficiencies and
from animal models of salmonella infection [1]. Such studies
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suggest the importance of a variety of immunological mech-
anisms including multiple cytokines [2], particularly the Th1
cytokines [3]; salmonellae, together with mycobacteria (another
class of intramacrophage pathogens), commonly cause invasive
disease among patients with primary immunodeficiencies char-
acterized by deficiency in the interleukin (IL)–12/IL-23–inter-
feron (IFN)–g axis [4].
At its simplest, the IL-12/IL-23–IFN-g axis is believed to con-
sist of 2 complementary components (figure 1): first, an IL-12/
IL-23 component, in which, in response to microbial stimuli,
macrophages and dendritic cells produce IL-12 and IL-23, which
act on NK and T cells and NKT cells [5]; and second, an IFN-
g component, in which IL-12 and IL-23 cause NK, T, and NKT
cells to produce IFN-g, which, in turn, acts on macrophages and
other nucleated cells. This results in cellular activation through
STAT1 and aids in the elimination of intramacrophage patho-
gens. Deficiencies have been identified in 5 proteins in this axis:
the b1 subunit of the IL-12 and IL-23 receptor (IL-12R/IL-23R),
the p40 subunit of IL-12 and IL-23 (IL-12/IL-23), chains 1 and
2 of the IFN-g receptor (IFN-gR), and STAT1. These deficiencies
are caused by mutations in autosomal genes and produce non-
functional or partially functional proteins [4]. The biology of IL-
12 and that of IL-23 are closely entwined with both cytokines
sharing the same p40 subunit and their receptors sharing the
same b1 subunit [6, 7]. Since the 2 presently described deficien-
cies in the IL-12/IL-23 component result in a deficiency of both
IL-12 and IL-23 signaling, these 2 cytokines must be considered
together when studying affected individuals and will, therefore,
be referred to as “IL-12/IL-23.”
Patients and methods. To compare immunity against salmo-
nellae with immunity against mycobacteria in humans, we re-
viewed data on 135 patients from 34 countries with confirmed
IL-12/IL-23–IFN-g–axis deficiency whom we have previously in-
vestigated and an additional 19 patients described in the medical
literature [4, 8]. This encompassed all patients worldwide known
to us to have IL-12/IL-23–IFN-g–axis deficiency at the time of
writing, and this process was therefore unselective. Patients had
been referred to clinical immunology/infectious disease services,
usually with a history of invasive atypical mycobacterial disease
with or without salmonella disease or with a family history of
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Figure 1. Interleukin (IL)–12/IL-23–interferon (IFN)–g axis showing (1)
the division between IL-12/IL-23 component and IFN-g component and (2)
the proteins that may be absent or deficient in humans: IL-12/IL-23 and IL-
12 receptor (R)/IL-23R (in IL-12/IL-23–component deficiency) and IFN-gR and
STAT1 (in IFN-g–component deficiency). For a more comprehensive figure,
see [6]. Mf/DC, macrophage/dendritic cell; T/NK, T cell/NK cell/NKT cell.
Table 1. Statistical analysis of salmonella and mycobacterial disease in 154 patients with interleukin (IL)–12/IL-23–interferon (IFN)–g–
axis deficiency, stratified according to component deficiency.
Deficiency
No. of
patients
Age, median
(range), years
Sex,
M:F
History of salmonella disease History of mycobacterial disease
Yes,
no. (%)
No,
no. (%) OR (95% CI)a Pb
Yes,
no. (%)
No,
no. (%) OR (95% CI)a Pb
IL-12/IL-23 component 71 9 (2–35) 29:42 31 (44%) 40 (56%) 1 55 (77%) 16 (23%) 1
IFN-g component 83 11 (1–62) 39:44 6 (7%) 77 (93%) 0.10 (0.03–0.28) .0000004 78 (94%) 5 (6%) 4.55 (1.44–16.33) .0061
a Exact method.
b Yate’s corrected x2.
such disease. Only a small minority (6%; 9/154) of patients had
been referred with a history of salmonella disease alone. After
exclusion of other known immunodeficiencies—including severe
combined immunodeficiency, chronic granulomatous disease,
AIDS, Di George syndrome, and antibody (IgG, IgA, and IgM)
deficiencies—patients were investigated for deficiency in both
components of the IL-12/IL-23–IFN-g axis. No patients were
receiving immunosuppressive therapy. We stratified patients ac-
cording to IL-12/IL-23–IFN-g–axis deficiency and determined
which patients had had salmonella and mycobacterial disease
(table 1). In the absence of a suitable control group, the number
of patients with IL-12/IL-23–component deficiency and a history
of each disease was compared with the number of patients with
IFN-g–component deficiency and the same disease. Odds ratios
(ORs) and 95% confidence intervals (CIs) were calculated with
Epi Info (version 6.04) by use of the exact method.
Results. The median age of patients (or age at death) was
similar in both the group with IL-12/IL-23–component defi-
ciency and the group with IFN-g–component deficiency (9 years
[range, 2–35 years] and 11 years [range, 1–62 years], respectively).
Surprisingly, we observed that 31 (44%) of 71 patients with IL-
12/IL-23–component deficiency had experienced invasive sal-
monella disease, compared with only 6 (7%) of 83 patients with
IFN-g–component deficiency. This difference is highly signifi-
cant (OR, 0.10; 95% CI, 0.03–0.28; ). In contrast,Pp .0000004
more patients with IFN-g–component deficiency (94%; 78/83)
had had mycobacterial disease, compared with patients with IL-
12/IL-23–component deficiency (77%; 55/71) (OR, 4.55; 95%
CI, 1.47–16.67; Pp .0061). All 9 patients with a history of sal-
monella disease alone had IL-12/IL-23–component deficiency.
These observations are striking and suggest that there are key
differences in the immune mechanisms operating against sal-
monellae and mycobacteria. IL-12/IL-23 appears to be important
for immunity against salmonella in humans and appears to op-
erate through IFN-g–independent, as well as IFN-g–dependent,
mechanisms.
Culture-positive salmonella disease occurred in 37 (24%) of
154 patients. Salmonella was typically isolated from extrain-
testinal sites, rather than from stool (for all except 1 patient),
and disease was often severe, with the referring clinician di-
agnosing sepsis in almost half of affected patients. Salmonella
disease was typically difficult to treat; patients often responded
poorly to conventional antibiotic therapy. Recurrent disease was
common, suggesting either inadequate courses of treatment or
a problem with secondary immunity against salmonella. All
except 1 of the serovars isolated were nontyphoidal. The median
age at the onset of the first salmonella infection among all 37
patients was 3 years (3 years [range, 1–12 years] for patients
with IL-12/IL-23–component deficiency and 1.5 years [range,
1–6 years] for patients with IFN-g–component deficiency). There
was no significant difference in the sex ratio of those patients
with IL-12/IL-23–IFN-g–axis deficiency with a history of sal-
monella disease ( ).P 1 .5
Discussion. The high prevalence of salmonella disease among
patients with IL-12/IL-23–component, as opposed to IFN-g–
component, deficiency suggests that the fundamental deficiency
in these patients is not simply a deficit in IFN-g production.
Although many of the actions of IL-12/IL-23 are mediated
through IFN-g, it has other biological functions, and the pres-
ent study should prompt further investigation into which of
these are important for immunity against salmonella in hu-
mans. Of the many cytokines implicated in immunity against
salmonella, tumor necrosis factor (TNF)–a and granulocyte-
macrophage colony-stimulating factor (GM-CSF) are partic-
ularly good candidates for mediating IFN-g–independent ac-
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tions of IL-12/IL-23, since both cytokines are produced by T
cells and/or NK cells in response to IL-12/IL-23 and both ac-
tivate macrophages [6, 7]. Animal models suggest a role for
both TNF-a [9] and GM-CSF [10] in immunity against sal-
monella. At present, there is no recognized human immuno-
deficiency of these cytokines or their receptors, although hu-
mans treated with the anti–TNF-a antibody, infliximab, do not
appear to show increased susceptibility to salmonella [11]. GM-
CSF has been used as an adjunctive therapy against infection
in clinical trials, but a beneficial effect is, so far, unproven [12].
Another potential IFN-g–independent action of IL-12/IL-23 is
its immunoregulatory role of promoting Th1 responses, which
are critical for effective cell-mediated immunity [6, 7].
Much of our current knowledge of the biology of IL-12/IL-
23 comes from animal studies, which also show a role for IL-
12/IL-23 in immunity against a wide variety of infections, in-
cluding those caused by viruses, bacteria, protozoa, and fungi
[6]. In contrast, salmonellae and mycobacteria appear to be the
only pathogens to which humans with IL-12/IL-23–component
deficiency show increased susceptibility, emphasizing the im-
portance of studying immunity against these diseases in hu-
mans [13]. Although the present study points to the importance
of IL-12/IL-23, this cytokine does not appear to be essential
for immunity against salmonella in all patients: we found high
titers of antisalmonella antibodies as evidence of exposure to
salmonella in 4 of 18 patients with IL-12/IL-23–component
deficiency who did not have a history of salmonella disease [8].
This difference in susceptibility to salmonella among patients
with IL-12/IL-23–component deficiency requires further inves-
tigation. Other patients who did not have a history of salmo-
nella disease may not have been exposed to salmonella. We also
found high titers of antisalmonella antibodies in 10 of 12 pa-
tients with IL-12/IL-23–component deficiency and a history of
salmonella disease [8], indicating that these patients can mount
satisfactory antibody responses to salmonella.
In conclusion, clinicians should consider the possibility of
an underlying IL-12/IL-23–IFN-g–axis deficiency in patients
with recurrent extraintestinal salmonella disease, as well as in
those with disseminated atypical mycobacterial disease. Such
deficiencies are probably underdiagnosed in patients with sal-
monella disease but are clinically significant, as infections often
require extended treatment, and live bacterial vaccines must be
avoided. The clinical observation that severe salmonella disease
is more likely in patients with IL-12/IL-23–component defi-
ciency than in patients with IFN-g–component deficiency sug-
gests that IL-12/IL-23 is a key cytokine for immunity against
salmonella in humans and merits both further investigation
into possible IFN-g–independent IL-12/IL-23–driven mecha-
nisms of immunity and dissection of the contributory role of
IL-12 and IL-23. It also suggests a possible role for recombinant
IL-12/IL-23 as immunotherapy for severe salmonella disease.
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